The practical angler : or, the art of trout-fishing more particularly applied to clear water

https://scholars.unh.edu/angling/1012/thumbnail.jp

Improving estimates of genetic maps: a meta-analysis-based approach

Inaccurate genetic ( or linkage ) maps can reduce the power to detect linkage, increase type I error, and distort haplotype and relationship inference. To improve the accuracy of existing maps, I propose a meta-analysis-based method that combines independent map estimates into a single estimate of the linkage map. The method uses the variance of each independent map estimate to combine them efficiently, whether the map estimates use the same set of markers or not. As compared with a joint analysis of the pooled genotype data, the proposed method is attractive for three reasons: (1) it has comparable efficiency to the maximum likelihood map estimate when the pooled data are homogeneous; (2) relative to existing map estimation methods, it can have increased efficiency when the pooled data are heterogeneous; and (3) it avoids the practical difficulties of pooling human subjects data. On the basis of simulated data modeled after two real data sets, the proposed method can reduce the sampling variation of linkage maps commonly used in whole-genome linkage scans. Furthermore, when the independent map estimates are also maximum likelihood estimates, the proposed method performs as well as or better than when they are estimated by the program CRIMAP. Since variance estimates of maps may not always be available, I demonstrate the feasibility of three different variance estimators. Overall, the method should prove useful to investigators who need map positions for markers not contained in publicly available maps, and to those who wish to minimize the negative effects of inaccurate maps. Genet. Epidemiol . 2007. © 2007 Wiley-Liss, Inc.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/56072/1/20221_ftp.pd

Assessing the admissibility of a new generation of forensic voice comparison testimony

This article provides a primer on forensic voice comparison (aka forensic speaker recognition), a branch of forensic science in which the forensic practitioner analyzes a voice recording in order to provide an expert opinion that will help the trier-of-fact determine the identity of the speaker. The article begins with an explanation of ways in which human speech varies within and between speakers. It then discusses different technical approaches that forensic practitioners have used to compare voice recordings, and frameworks of reasoning that practitioners have used for evaluating the evidence and reporting its strength. It then discusses procedures for empirical validation of the performance of forensic voice comparison systems. It also discusses the potential influence of contextual bias and ways to reduce this. Building on this scientific foundation, the article then offers analysis, commentary, and recommendations on how courts evaluate the admissibility of forensic voice comparison testimony under the Daubert and Frye standards. It reviews past rulings such as U.S. v. Angleton, 269 F.Supp 2nd 892 (S.D. Tex. 2003) that found expert testimony based on the spectrographic approach inadmissible under Daubert. The article also offers a detailed analysis of the evidence presented in the recent Daubert hearing in U.S. v. Ahmed, et al. 2015 EDNY 12-CR-661, which included testimony based on the newer automatic approach. The scientific testimony proffered in Ahmed is used to illustrate the issues courts are likely to face when considering the admissibility of forensic voice comparison testimony in the future. The article concludes with a discussion of how proponents of forensic voice comparison testimony might meet a reasonably rigorous application of the Daubert standard and thereby ensure that such testimony is sufficiently trustworthy to be used in court

Efficacy, safety, and tolerability of travoprost 0.004% BAK-free versus prior treatment with latanoprost 0.005% in Japanese patients

Michael J Miyashiro1, Samuel C Lo2, Jeanette A Stewart3, William C Stewart31Ludwig Ophthalmology Centre, Hilo, HI, USA; 2Private Practice, Honolulu, HI, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAObjective: To examine the efficacy, safety, and tolerability of travoprost 0.004% benzalkonium chloride (BAK)-free compared with previous use of latanoprost 0.005% in Japanese patients living in the US who had primary open-angle glaucoma or ocular hypertension.Methods: This was an open-label, multicenter, bilateral, intraindividual, and active-controlled study in which 20 Japanese American patients with primary open-angle glaucoma or ocular hypertension who had been on latanoprost 0.005% monotherapy were changed to monotherapy with travoprost 0.004% BAK-free daily for 12 weeks. Patients were administered the same series of tests to evaluate the efficacy, safety, and tolerability of latanoprost at the baseline visit and of travoprost BAK-free at the week 12 visit.Results: No significant difference in mean intraocular pressure (IOP) was observed between latanoprost monotherapy at baseline and travoprost BAK-free monotherapy after 12 weeks (P = 0.76), nor were significant differences noted in mean ocular hyperemia, visual acuity, corneal fluorescein staining, or overall scores from the Ocular Surface Disease Index. Patients had a significantly shorter mean tear breakup time while on latanoprost compared with travoprost BAK-free (P = 0.0094). Significantly more patients preferred travoprost BAK-free monotherapy over latanoprost monotherapy (14 versus 6; P = 0.011).Conclusion: The results of this study suggest that Japanese American patients transitioned from latanoprost 0.005% monotherapy to travoprost 0.004% BAK-free can expect similar IOP control and some improvement in anterior segment signs. This transition study showed a strong patient preference for travoprost BAK-free over latanoprost, at a ratio of more than 2:1.Keywords: glaucoma, intraocular pressure, latanoprost, prostaglandin analog, travopros

Improving Estimates of Genetic Maps: A Maximum Likelihood Approach

As a result of previous large, multipoint linkage studies there is a substantial amount of existing marker data. Due to the increased sample size, genetic maps estimated from these data could be more accurate than publicly available maps. However, current methods for map estimation are restricted to data sets containing pedigrees with a small number of individuals, or cannot make full use of marker data that are observed at several loci on members of large, extended pedigrees. In this article, a maximum likelihood (ML) method for map estimation that can make full use of the marker data in a large, multipoint linkage study is described. The method is applied to replicate sets of simulated marker data involving seven linked loci, and pedigree structures based on the real multipoint linkage study of Abkevich et al. (2003, American Journal of Human Genetics 73, 1271–1281). The variance of the ML estimate is accurately estimated, and tests of both simple and composite null hypotheses are performed. An efficient procedure for combining map estimates over data sets is also suggested.Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/66271/1/j.1541-0420.2006.00532.x.pd

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy

J Charles Henry1, James H Peace2, Jeanette A Stewart3,4, William C Stewart3,41Little Rock Eye Clinic, Little Rock, AR, USA; 2Diabetic Eye Medical Clinic, Inglewood, CA, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas,TX, USA; 4Carolina Eye Institute, University of South Carolina, School of Medicine, Columbia, SC, USAPurpose: To evaluate the efficacy, safety and tolerability of changing to travoprost BAK-free from prior prostaglandin therapy in patients with primary open-angle glaucoma or ocular hypertension.Design: Prospective, multi-center, historical control study.Methods: Patients treated with latanoprost or bimatoprost who needed alternative therapy due to tolerability issues were enrolled. Patients were surveyed using the Ocular Surface Disease Index (OSDI) to evaluate OSD symptoms prior to changing to travoprost BAK-free dosed once every evening. Patients were re-evaluated 3 months later.Results: In 691 patients, travoprost BAK-free demonstrated improved mean OSDI scores compared to either latanoprost or bimatoprost (p < 0.0001). Patients having any baseline OSD symptoms (n = 235) demonstrated significant improvement after switching to travoprost BAK-free (p < 0.0001). In 70.2% of these patients, symptoms were reduced in severity by at least 1 level. After changing medications to travoprost BAK-free, mean intraocular pressure (IOP) was significantly decreased (p < 0.0001). Overall, 72.4% preferred travoprost BAK-free (p < 0.0001, travoprost BAK-free vs prior therapy). Travoprost BAK-free demonstrated less conjunctival hyperemia than either prior therapy (p < 0.0001).Conclusions: Patients previously treated with a BAK-preserved prostaglandin analog who are changed to travoprost BAK-free have clinically and statistically significant improvement in their OSD symptoms, decreased hyperemia, and equal or better IOP control.Keywords: glaucoma, prostaglandin analog, travoprost, latanoprost, bimatoprost, preservative, benzalkonium chloride, ocular surface diseas

A comfort comparison of travoprost BAK-free 0.004% versus latanoprost 0.005% in patients with primary open-angle glaucoma or ocular hypertension

David A Godfrey1, Lee S Peplinski2, Jeanette A Stewart3, William C Stewart31Glaucoma Associates of Texas, Dallas, TX, USA; 2Kentuckiana Institute for Eye Research, Louisville, KY, USA; 3PRN Pharmaceutical Research Network, LLC, Dallas, TX, USAPurpose: To determine the short-term comfort after a single dose of travoprost BAK-free compared to latanoprost in primary open-angle glaucoma or ocular hypertensive patients.Design: Prospective, double-masked, randomized comparison of two separate active agents dosed once in opposite eyes.Methods: At Visit 1, qualified patients began a glaucoma medicine-free period for three days. At Visit 2, patients were randomly assigned to travoprost BAK-free or latanoprost in opposite eyes. Following dosing in each eye, patients completed a visual analog scale (VAS score, 0–100 mm) at specified time intervals and a comfort survey.Results: In 54 completed subjects, no difference existed five seconds after dosing, in comfort on the VAS between latanoprost (7.1 ± 16.2 mm) and travoprost BAK-free (7.8 ± 16.1 mm, P = 0.53). Also no differences existed between treatments following dosing for discomfort at individual timepoints past five seconds, peak discomfort or the time required to return to baseline comfort (P > 0.05). In addition, the comfort survey demonstrated no difference between products for burning, stinging, foreign body sensation, overall comfort and general acceptance between the products, both for absolute levels and changes from baseline (P > 0.05).Conclusion: Following a single instillation, both latanoprost and travoprost BAK-free exhibit similar comfort scores.Keywords: comfort, travoprost BAK-free, latanoprost, glaucoma, ocular hypertensio